FLT3 and acute myeloid leukemia: In a phase III study, the combination of midostaurin with standard chemotherapy in patients with FLT3‐mutat AML afforded significant survival benefit with a remarkable elevated median OS (74.7 vs 25.6 months), and reduced cumulative incidence of relapse.[13] Similarly, the addition of ABT199 to decitabine or azacitidine exhibited favorable overall response rate with a CR rate of around 67% in treatment‐naive, elderly patients with AML.[14] Recently, different small molecule inhibitors with diverse potency and specificity were combined to treat heterogeneous AML.